Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 7/20 | 1.00 |
| ▸ | SLC40A1 | Q9NP59 | 9/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.63 |
| ▸ | NFKBIA | P25963 | 2/20 | 0.63 |
| ▸ | G6PD | P11413 | 1/20 | 0.63 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.63 |
| ▸ | METAP2 | P50579 | 1/20 | 0.63 |
| ▸ | METAP1 | P53582 | 1/20 | 0.63 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.63 |
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | RELA | Q04206 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30372036 | 1.00 | GLO1 (1.00) | GLO1SLC40A1TDP1NFKBIAG6PD | |
| SCHEMBL3107794 | 0.80 | SLC40A1 (0.69) | GLO1SLC40A1TDP1NFKBIAAGTR1 | |
| SCHEMBL442367 | 0.78 | SLC40A1 (1.00) | GLO1SLC40A1TDP1NFKBIAG6PD | |
| SCHEMBL28028822 | 0.77 | GLO1 (0.62) | GLO1MEN1KMT2A | |
| SCHEMBL13485951 | 0.77 | GLO1 (0.64) | GLO1SLC40A1TDP1NFKBIAG6PD | |
| SCHEMBL7746129 | 0.77 | SLC40A1 (0.97) | GLO1SLC40A1TDP1NFKBIAG6PD | |
| SCHEMBL11972946 | 0.77 | SLC40A1 (1.00) | GLO1SLC40A1TDP1NFKBIAG6PD | |
| SCHEMBL6860415 | 0.76 | GLO1 (0.70) | GLO1SLC40A1TDP1NFKBIAG6PD | |
| SCHEMBL22764864 | 0.76 | GLO1 (0.60) | GLO1SLC40A1AGTR1PAX8ALOX15 | |
| SCHEMBL11469225 | 0.76 | GLO1 (0.60) | GLO1SLC40A1TDP1NFKBIAG6PD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041653-A1 | COMPOSITION AND METHODS FOR THE DESIGN AND DEVELOPMENT OF METALLO-ENZYME INHIBITORS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041653-A1 | COMPOSITION AND METHODS FOR THE DESIGN AND DEVELOPMENT OF METALLO-ENZYME INHIBITORS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-02-18 | — | — | US | disclosed |
| EP-0991624-B1 | PHENYLALKYL DERIVATIVES WITH THROMBIN-INHIBITING EFFECT | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-11-19 | — | — | EP | disclosed |
| EP-0675358-B1 | Monitoring water treatment agent in-system concentration and regulating dosage | NALCO CHEMICAL CO (US) | 2003-07-02 | — | — | EP | disclosed |
| EP-0991624-A1 | PHENYLALKYL DERIVATIVES WITH THROMBIN-INHIBITING EFFECT | Boehringer Ingelheim Pharma KG (DE) | 2000-04-12 | — | — | EP | disclosed |
| WO-1999000371-A1 | PHENYLALKYL DERIVATIVES WITH THROMBIN-INHIBITING EFFECT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1999-01-07 | — | — | WO | disclosed |
| EP-0675358-A1 | Monitoring water treatment agent in-system concentration and regulating dosage | NALCO CHEMICAL COMPANY (US) | 1995-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041653-A1 | COMPOSITION AND METHODS FOR THE DESIGN AND DEVELOPMENT OF METALLO-ENZYME INHIBITORS | HELZ, MMEL1, GAA | GLO1 2965/4885SLC40A1 408/4885TDP1 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.